Suramin, a synthetic polysulfonated anionic compound, is known to abrogate the activity of a variety of growth factors that serve as ligands for receptor-class protein-tyrosine kinases. Based on this information, we initially hypothesized that suramin treatment would be associated with decreased tyrosine phosphorylation. Upon testing this hypothesis in prostate cancer cell lines, we found that the most conspicuous effect of suramin was to increase the tyrosine phosphorylation of several distinct proteins. Further analyses indicate that suramin-induced increases in tyrosine phosphorylation represent a generalized, but not universal, phenomenon found in cell lines derived from a variety of human tissues. These rapid and specific suramin-induced alterations represent a novel finding for a nonpolypeptide pharmaceutical agent and question the hypothesis that suramin exerts its antitumor action simply by abrogation of growth factor action. (J. Clin. Invest. 1992Invest. . 90:2166Invest. -2174 
Introduction
Suramin is the hexasodium salt of carbonyl bis[8-(3-aminobenzamido) 4 -methylbenzamido] -naphthalene-4,6,8 trisulfonate ( Fig. 1) . A synthetic compound, suramin was originally synthesized in 1916 by Bayer AG as part of an ongoing search for antitrypanosomal chemotherapeutic agents. After demonstration ofactivity against trypanosomes in model systems, and the subsequent discovery of its activity against onchercerciasis, suramin has been used to treat parasite-infected patients throughout the world since the 1 920s (1) .
In 1984 suramin was reported to dissociate platelet-derived growth factor (PDGF) 1 from its receptor and block the binding of PDGF to cell membranes (2) . The mechanism whereby suramin inhibits PDGF binding to its receptor is secondary to a direct attachment of suramin to the PDGF molecule (3) . In v-sis transformed fibroblasts, where activation of the PDGF receptor is a requisite for transformation, suramin induces phenotypic reversion (4) and decreases the extent of cellular tyrosine phosphorylation (5) . Subsequent studies indicate that suramin can inhibit the activity ofa number of peptides known to stimulate cellular tyrosine phosphorylation including basic fibroblast growth factor (bFGF) (6, 7) , the product of the hst/ K-fgf gene (8) , interleukin 2 (9) , and scatter factor (also known as hepatocyte growth factor) (10) .
Beginning in 1987, prompted by reports that suramin reversed a variety of growth factor-induced actions, suramin was administered in clinical trials and found to have antitumor activity ( 11 ) . More recently, in both model systems (12) (13) (14) and in clinical trials ( 15, 16) , suramin has been demonstrated to have antitumor activity against prostatic cancer.
Given the fact that suramin antagonizes the activity of a variety of growth factors known to increase cellular tyrosine phosphorylation (see reference 17) , and given the fact that suramin has antitumor activity against cell lines derived from prostatic cancer patients ( 12, 13) , we initially hypothesized that suramin treatment would decrease tyrosine phosphorylation in prostate cancer cells. Upon testing this hypothesis, we were surprised to find that the most conspicuous effect of suramin was a rapid (within seconds) and marked increase in the tyrosine phosphorylation of several cellular prqteins.
Methods
Cell culture. The androgen-insensitive PC3 and DU 145 and the androgen-sensitive LNCaP prostate cancer cell lines were obtained from the American Type Culture Collection (ATCC). PC3M, a highly metastatic variant of PC3 cells, was obtained from Dr. J. M. Kozlowski, Northwestern Medical School, Evanston, IL. The colon cell lines HT29, COLO 205, and SW620, and the leukemia cell lines (CEM and HL60) were obtained from ATCC. The colon cell lines (designated 630) and NCI-H716 (designated 716), originally described by Dr. A. Gazdar and colleagues (18) , were obtained from the laboratory of Dr. C. Allegra. The (21 ) . Bethesda Research Laboratories (Gaithersburg, MD) size markers were used for determination ofprotein size. After transfer to nitrocellulose, filters were blotted as previously described (22) .
Preparation of membrane-enriched and cytosolic cell fractions. Cells were lysed in ice-cold hypotonic lysing buffer (20 mM pH 7.6 Hepes with 1 mM EDTA, 1 mM vanadate, 1 mM PMSF, 20 ,g/ml leupeptin, and 20 qg/ ml aprotinin) and all subsequent steps were performed at 4°C. Cells were scraped from the tissue culture plate, repetitively passed through a 23-gauge needle, and nuclei were pelleted for 10 minutes at 1,000 g. The supernatant was then removed and recentrifuged at 176,000 g for 1 h. The remaining supernatant (cytosolic fraction) and the TNESV extractable portion of the pellet (membrane fraction) were size-fractionated by SDS-PAGE after boiling in LSB.
Antibodies. Immunoprecipitations. Cellular lysates were prepared with TNESV supplemented with protease-inhibitors as described above. After equalization of protein between samples (300-600 jug of protein per sample), antibodies were added for 1-4 h at 40C. Rabbit antibodies were immunoprecipitated with the aid of protein A-Sepharose beads (Pharmacia, Inc., Piscataway, NJ). Mouse monoclonal antibodies were immunoprecipitated with the aid of protein A-Sepharose beads coated with affinity-purified rabbit anti-mouse antisera (Cappel Laboratories, West Chester, PA). Beads were then washed twice with lysing buffer before boiling in LSB and fractionation by SDS-PAGE.
Immune-complex kinase assays and V8 digests. Immune-complex kinase assays and proteolytic digests with V8 protease (Worthington Biochemical Corp., Freehold, NJ) were performed exactly as previously described (22 
Results
To determine the effects of suramin on tyrosine phosphorylation in an androgen-insensitive prostate cancer cell line, lysates derived from PC3 cells were examined by anti-phosphotyrosine immunoblotting (see Fig. 2 A) . PC3 cells express several prominent tyrosine phosphorylated proteins of -60 and 120 kD as detected by the 4G10 monoclonal antibody. Within seconds after treatment of cells with 300 ,ug/ ml suramin, a suramin concentration utilized in the clinical setting ( 15, 16, 25) , several new tyrosine-phosphorylated bands were readily detected in the cellular lysates and (in some cases) the p120 band became less prominent. The most conspicuous of the newly tyrosine-phosphorylated proteins had molecular masses of -75 and 135 kD. To verify the specificity of the 4G10 antibody, phenylphosphate ( 10 mM) was preincubated with 4G10 before immunoblotting. Under these conditions, no bands were detected in suramin-treated or untreated PC3 cells (data not shown). To determine whether these bands were detected by a second and distinct anti-phosphotyrosine antibody, we immunoblotted these same lysates using monoclonal antibody PY20 (see Fig. 2 B) . In untreated PC3 cells, the 120-kD band was readily detectable after immunoblotting with PY20. In contrast, the 60-kD band was much less prominent in blots with PY20 as compared to 4G10. After suramin addition, the prominent tyrosine phosphorylated bands at -75 and 135 kD Ag/ml suramin.
To ascertain whether the suramin-induced changes in tyrosine phosphorylation were indicative ofbroader changes in cellular phosphorylation, detergent lysates derived from metabolically labeled ([32P]orthophosphate) PC3 cells were examined by SDS-PAGE after suramin treatment. No differences were noted in the phosphorylated protein pattern detected in these assays, indicating that the suramin-induced changes in phosphotyrosine were not the result ofglobal changes in phosphorylation (data not shown).
The rapidity of the changes in tyrosine phosphorylation after suramin treatment suggested that suramin interacts with a component of the culture media (such as serum) and/or a cellular component in direct contact with the extracellular environment. Because the initial experiments were performed in the presence of 10% fetal calf serum, we questioned whether or not serum would affect the suramin-induced changes in tyrosine phosphorylation. Thus, PC3 cells were washed twice with PBS and placed in RPMI without serum supplementation ("0"), RPMI plus 10% human platelet-poor plasma ("HP"), or RPMI plus 10% human serum ("HS"). Regardless of the media employed, 300 ,ug/ml of suramin induced a rapid increase in the phosphotyrosine content of the 75-and 1 35-kD bands (Fig. 3) . In other experiments, similar suramin-induced changes were noted for cells cultured in serum-free media for 72 h (data not shown). Thus, suramin-induced changes are not directly dependent upon interactions between suramin and serum components. Because ofthe rapidity ofthe changes, and because the entry of suramin into cells is limited by size and charge, these studies suggest that rapid suramin-induced increases in tyrosine phosphorylation are the result ofan interaction between suramin and a component ofthe cell ( cells were treated with 300 ,g/ml suramin for varying periods of time. As shown in Fig. 4 A, the tyrosine phosphorylated bands of 75 and 135 kD were readily detected between 10 and 40 min after suramin addition. However, 160 min later, the tyrosine phosphorylation pattern was not substantially different from baseline. Also of note, the prominence of the p120 band varied in an inverse manner with that ofthe p75 and p 135 bands. After 72 h of continuous exposure to 50, 150, or 300 tig/ml suramin (Fig. 4 B) , no differences were noted in PC3
proteins as assessed by the anti-phosphotyrosine immunoblots. These data indicate that the suramin-induced changes in tyrosine phosphorylation are both rapidly induced and relatively short-lived. The relatively short-lived drug-induced changes could be the result ofalterations in the drug itself, or to a cellular "desensitization" to the drug's action. To distinguish between these possibilities, we applied suramin to PC3 cells and measured the suramin concentration in the culture media 1 min and 3 h later and found no differences (279 vs. 294 ,ug/ml, respectively). Furthermore, by this HPLC-based assay, we found no evidence for suramin degradation or metabolism. To determine whether the suramin-induced tyrosine phosphorylation desensitizes, the response to suramin was studied at various times after a 2-h suramin pretreatment. As shown in Fig. 5, 2 uced tyrosine phosphorylation pattern was unchanged, indicating reversibility of the desensitization process. The minor differences between the untreated lanes in this figure can be attributed to sample variation. These studies demonstrate that the relatively brief duration of the suramin-induced responses is not the result of suramin degradation, but rather the result of desensitization to the action of the drug.
To determine the dose-response curve for suramin-induced tyrosine phosphorylation in PC3 cells, cells were treated with 0, 30, 100, 300, 1,000, and 3,000 ,ug/ml of suramin (Fig. 6 A) . From these studies it is clear that the suramin-induced alterations in tyrosine phosphorylation of the 75-and 1 35-kD proteins occurred at dosages of > 100 Ag/ml in the PC3 cells.
These experiments also emphasize the reciprocal relationship between tyrosine phosphorylation ofthe p1 20 and p1 35 bands.
Because suramin is clinically used at a serum level of 300 tg/ml ( 15, 16, 24) , it is clear that suramin-induced changes in tyrosine phosphorylation can occur at clinically relevant drug concentrations within this cell line. To determine whether or not these suramin-induced alterations in tyrosine phosphorylation were detectable in other prostate cancer cell lines, lysates derived from suramin treated PC3M, DUl45, and LNCaP cells were immunoblotted with the 4G10 monoclonal antiphosphotyrosine antibody (Fig. 6, B-D) . The untreated PC3M and LNCaP cells displayed a tyrosine phosphorylation pattern very similar to that of the PC3 cells, with prominent proteins detected at 60 and 120 kD. In contrast, the pattern of tyrosine phosphorylated proteins in the DU 145 cells was distinct. In addition to the tyrosine phosphorylated 60-and 120-kD proteins, prominent bands were also detected at 54 and 57 kD. (Fig. 7 C) (Fig. 7 A) . Suramin also induced a modest decrease in tyrosine phosphorylation of a 120-kD band, however, these effects were limited to PC3 (Fig. 7 C) and HT29 cells (Fig. 7 A) . Thus, although acute suramin-induced decreases in tyrosine phosphorylation are detectable, they are relatively limited in comparison to suramin-induced increases in tyrosine phosphorylation. From these data we conclude that suramin-induced alterations in tyrosine phosphorylations are a common feature ofmany, but not all, cell lines. As a generalization, cells with the suramin-induced 75-and 135-kD bands were derived from epithelial adenocarcinomas. (Fig. 7 D) . In several cell lines, for instance the gastric-derived Suramin is a highly sulfated polyanionic molecule at physiologic pH. To determine whether or not other polyanionic compounds could induce acute alterations in tyrosine phosphorylation, heparin (1-1,820 U/ml), heparan sulfate ,gg/ml), glycosaminoglycans purified from urine of suramintreated patients jg/ml, see reference 26) and pentosan polysulfate 200 ,ug/ml) were assayed in the 10-min PC3 tyrosine phosphorylation assay. None of these compounds caused any alterations in tyrosine phosphorylation (data not shown). Protamine sulfate (3-100 ,ug/ml), a compound (like suramin) that reverses bFGF and PDGF action (27, 28), also had no effect on tyrosine phosphorylation in PC3 cells. In addition, simultaneous additions of heparin and suramin did not demonstrate interactions between these two molecules (data not shown). These data demonstrate that the suramin-induced alterations in tyrosine phosphorylation are specific for suramin, and not simply dependent upon the presence of a highly charged polyanion.
Alterations in protein-tyrosine phosphorylation may be due to either activation of protein-tyrosine kinases or inhibition of protein-tyrosine phosphatases. To assess the possibility of kinase activation, we performed in vitro immune-complex kinase assays utilizing 32P-labeled ATP after anti-phosphotyrosine immunoprecipitations. Under such circumstances, autophosphorylating kinases, and in vitro kinase substrates that are immunoprecipitated by anti-phosphotyrosine antibodies will be detected as 32P-labeled proteins. After size-fractionation of the reaction products by SDS-PAGE (Fig. 8) , a prominent 75-kD band was detectable in the samples derived from suramin-treated PC3 cells as well as the colon-derived cell lines (HT 29, SW 620, and COLO 205). Samples derived from the WIDR cell line (also colon-derived) had a less prominent, but detectable, band at 75 kD as well. Of note, the 135-kD band detected in immunoblots after suramin treatment was not detected in the immune-complex kinase assays, suggesting that the mechanism(s) of suramin-induced phosphorylation may differ for the 75-and 135-kD proteins. Similar results were obtained in the PC3 and SW620 cells (other cells were not tested) when using antibody PY20 or 4G10 (not shown). These results indicate that anti-phosphotyrosine immunoprecipitates derived from suramin-treated PC3 cells contain increased kinase activity relative to untreated PC3 cells and suggest that suramin-induced increases in cellular phosphorylation may be the result of enhanced kinase activity.
To determine if the 75-kD protein detected after suramin treatment is the same in prostate and colon cells, digestions with V8 protease were performed (using p75 labeled in immune-complex kinase reactions). Analysis of the 32P-labeled fragments by SDS-PAGE revealed peptides of identical size (Fig. 9) , suggesting that suramin-induced tyrosine phosphorylation of p75 represents the same protein in cells derived from prostatic and colonic neoplasms. V8 proteolysis also confirms that the 75-kD protein recognized by the PY20 monoclonal antibody is highly similar, if not identical, to that recognized by the 4G 10 antibody (Fig. 9 ).
Discussion
The exact mechanism of suramin action has not been determined from these studies. The simplest hypothesis is that suramin directly alters the enzymatic activity of a protein-tyrosine kinase. However, our results do not rule out the possibility that a tyrosine phosphatase(s) is directly or indirectly involved, particularly in the phosphorylation changes detected in the 120-kD band. It is also possible that suramin acts via an "intermediate" compound which in turn modulates the activity of a protein-tyrosine kinase or phosphatase. Such an intermediate mechanism has recently been postulated for suramin-induced epidermal growth factor (EGF) receptor activation in the A43 1 cell line (29) . In A43 1 cells, suramin treatment increases TGFa (as detected by radioimmunoassay) in the culture media in a time-dependent fashion and increases cellular tyrosine phosphorylation. In that study (29) , neither TGF-a nor alterations in tyrosine phosphorylation were noted within the first several (Fig. 3 B) , no differences in TGF-a release into conditioned medium as detected by RIA (data not shown), and no tyrosine phosphorylation changes in proteins of 170 kD (see Figures 2-7) . Thus, though it is plausible that suramin-induced alterations in cellular tyrosine phosphorylation are secondary to release of an intermediate factor release, there is no evidence in PC3 cells for this factor being TGF-a.
The suramin-induced effects on tyrosine phosphorylation are reminiscent of a ligand-receptor interaction in several respects: suramin induces the response within seconds of exposure to the cell, the response desensitizes after a relatively brief period ofcontinuous exposure, and the desensitization is reversible after subsequent removal of the ligand. Thus, based upon these data, we postulate that suramin, or a suramin-induced intermediate, interacts with a receptor-like moiety at the cell surface. Plausible candidates for the tyrosine-phosphorylated proteins detected in these studies include a variety of tyrosine kinases, and their substrates, with molecular masses of -75 and 135 kD. Tyrosine kinases of -135 kD include members ofthe FGF receptor family and the met proto-oncogene (hepatocyte growth factor receptor) (see references 17 and 30). Members of the trk family (31, 32) , ret (33) , and the recently described 72-kD syk kinase (34) are also within the expected size ranges; however, these proteins are expressed in a tissue-specific manner that is not compatible with that found for the suramin-induced tyrosine phosphorylations. Potential tyrosine-phosphorylated "substrate" molecules include PLC-y (35, 36), the ras GTPase-activating protein (GAP) (37, 38) , and/or the 80-, 120-, 125-, and 130-kD tyrosine-phosphorylated proteins initially identified in fibroblasts expressing activated src genes (23 (39) and can induce production of antiproliferative heparan sulfates (26) . The rapid effects of suramin on tyrosine phosphorylation, at first glance, appear to be antithetical to suramin's role as an antitumor agent. However, these results suggest an alternative hypothesis for suramin's antitumor mechanism of action. Based upon our data, we hypothesize that a portion ofthe antitumor effect of suramin may be due to the activation, and subsequent down-regulation, of a signal Figure 9 . Singularity of the p75 protein detected in anti-phosphotyrosine immune-complex kinase assays. Immune-complex kinase assays were performed on PC3 or SW620 lysates according to the methods denoted in Fig. 8 . After SDS-PAGE, the suramin-induced p75 band was excised and cleaved with V8 protease. Products ofthe proteolytic digestion were then size-fractionated by SDS-PAGE ( 14% gel) and visualized by autoradiography. The mobility of the molecular size markers is shown in kilodaltons.
transduction pathway essential for cancer cell growth. It is also plausible that alterations in signal transduction may play a role in suramin's antiparasitic action. In summary, these studies clearly demonstrate an acute and marked alteration in the tyrosine phosphorylation of several cellular proteins in response to suramin treatment. In some cell lines, this response occurs at levels of the drug used in the clinical setting. To our knowledge, these studies represent the first demonstration ofenhanced tyrosine phosphorylation by a nonpolypeptide pharmaceutical agent. Though our initial studies were restricted to prostate cancer cell lines, it is readily apparent that suramin can elicit similar changes in an assortment of cell lines derived from a variety of human tissues. Suramin at a concentration of 1,000 Atg/ml (+) was added to the cell media 10 min before cell lysis and proteins were immunoprecipitated with the monoclonal anti-phosphotyrosine antibody PY20. After performing immune-complex kinase assays with 32P-labeled ATP, the reactions products were size fractionated by SDS-PAGE and visualized by autoradiography. The electrophoretic mobility of molecular size markers is shown in kilodaltons.
